Scotiabank Forecasts Strong Price Appreciation for Agios Pharmaceuticals (NASDAQ:AGIO) Stock

Agios Pharmaceuticals (NASDAQ:AGIO) had its target price boosted by Scotiabank from $51.00 to $53.00 in a research report issued to clients and investors on Friday, Benzinga reports. The brokerage presently has a “sector outperform” rating on the biopharmaceutical company’s stock. Scotiabank’s target price would suggest a potential upside of 19.50% from the stock’s current price.

Several other research firms have also recently weighed in on AGIO. StockNews.com raised Agios Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Wednesday, October 16th. Royal Bank of Canada reiterated an “outperform” rating and issued a $55.00 price objective on shares of Agios Pharmaceuticals in a report on Thursday, September 19th. Leerink Partners cut shares of Agios Pharmaceuticals from an “outperform” rating to a “market perform” rating and dropped their target price for the company from $60.00 to $56.00 in a report on Friday, September 27th. Raymond James reissued an “outperform” rating and set a $51.00 price target on shares of Agios Pharmaceuticals in a research report on Thursday, October 10th. Finally, Cantor Fitzgerald reissued an “overweight” rating on shares of Agios Pharmaceuticals in a research note on Friday, September 20th. Five analysts have rated the stock with a hold rating and four have given a buy rating to the company. Based on data from MarketBeat, Agios Pharmaceuticals presently has a consensus rating of “Hold” and an average price target of $52.33.

Agios Pharmaceuticals Stock Performance

Shares of Agios Pharmaceuticals stock traded down $0.08 during midday trading on Friday, reaching $44.35. 62,930 shares of the company’s stock traded hands, compared to its average volume of 686,784. The company has a market cap of $2.52 billion, a PE ratio of -6.93, a price-to-earnings-growth ratio of 0.47 and a beta of 0.75. The stock has a 50 day moving average of $44.68 and a 200-day moving average of $42.01. Agios Pharmaceuticals has a 12 month low of $20.40 and a 12 month high of $53.28.

Agios Pharmaceuticals (NASDAQ:AGIO) last issued its quarterly earnings data on Thursday, August 1st. The biopharmaceutical company reported ($1.69) EPS for the quarter, missing the consensus estimate of ($1.60) by ($0.09). The company had revenue of $8.60 million during the quarter, compared to the consensus estimate of $9.34 million. Agios Pharmaceuticals had a negative return on equity of 47.05% and a negative net margin of 1,165.69%. The firm’s revenue for the quarter was up 28.4% compared to the same quarter last year. During the same quarter last year, the company posted ($1.51) earnings per share. On average, equities analysts anticipate that Agios Pharmaceuticals will post 7.54 earnings per share for the current fiscal year.

Insider Transactions at Agios Pharmaceuticals

In related news, CEO Brian Goff sold 11,091 shares of the business’s stock in a transaction that occurred on Thursday, August 8th. The shares were sold at an average price of $42.75, for a total value of $474,140.25. Following the completion of the transaction, the chief executive officer now directly owns 78,792 shares in the company, valued at $3,368,358. The trade was a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. In other news, CEO Brian Goff sold 11,091 shares of the business’s stock in a transaction that occurred on Thursday, August 8th. The shares were sold at an average price of $42.75, for a total transaction of $474,140.25. Following the completion of the transaction, the chief executive officer now directly owns 78,792 shares of the company’s stock, valued at $3,368,358. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO Cecilia Jones sold 2,542 shares of the firm’s stock in a transaction that occurred on Thursday, September 26th. The stock was sold at an average price of $49.03, for a total transaction of $124,634.26. Following the completion of the sale, the chief financial officer now owns 20,158 shares in the company, valued at $988,346.74. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders own 4.93% of the company’s stock.

Institutional Trading of Agios Pharmaceuticals

Several large investors have recently modified their holdings of the company. Nordea Investment Management AB boosted its position in Agios Pharmaceuticals by 13.0% in the first quarter. Nordea Investment Management AB now owns 266,588 shares of the biopharmaceutical company’s stock worth $7,824,000 after purchasing an additional 30,764 shares during the last quarter. Caxton Associates LP bought a new stake in Agios Pharmaceuticals during the first quarter valued at approximately $1,087,000. Vanguard Group Inc. increased its holdings in Agios Pharmaceuticals by 1.1% during the fourth quarter. Vanguard Group Inc. now owns 5,527,438 shares of the biopharmaceutical company’s stock valued at $123,096,000 after buying an additional 59,851 shares during the last quarter. D. E. Shaw & Co. Inc. increased its holdings in Agios Pharmaceuticals by 87.3% during the second quarter. D. E. Shaw & Co. Inc. now owns 678,234 shares of the biopharmaceutical company’s stock valued at $29,245,000 after buying an additional 316,100 shares during the last quarter. Finally, Price T Rowe Associates Inc. MD boosted its stake in shares of Agios Pharmaceuticals by 23.9% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 2,012,993 shares of the biopharmaceutical company’s stock worth $58,861,000 after acquiring an additional 388,381 shares during the last quarter.

Agios Pharmaceuticals Company Profile

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.